Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.S. Pharma Industry Analysis

UpdatedNov 08, 2025
DataAggregated Company Financials
Companies296
  • 7D2.0%
  • 3M20.4%
  • 1Y4.4%
  • YTD10.2%

Over the last 7 days, the Pharma industry has risen 2.0%, driven by gains from Eli Lilly of 7.1%. In the same time, Zoetis was down 17%. This means that the industry has gained 4.4% over the past year. As for the next few years, earnings are expected to grow by 12% per annum.

Industry Valuation and Performance

Has the U.S. Pharma Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Sun, 09 Nov 2025US$2.0tUS$396.2bUS$70.9b17.4x27.9x5x
Tue, 07 Oct 2025US$1.9tUS$387.9bUS$60.9b19.2x31.7x5x
Thu, 04 Sep 2025US$1.8tUS$387.9bUS$61.0b19.5x29.2x4.6x
Sat, 02 Aug 2025US$1.7tUS$381.9bUS$55.1b17.8x30.7x4.4x
Mon, 30 Jun 2025US$1.7tUS$382.7bUS$61.2b17.5x27.9x4.5x
Wed, 28 May 2025US$1.6tUS$382.6bUS$61.2b17.5x26.9x4.3x
Fri, 25 Apr 2025US$1.7tUS$380.6bUS$48.4b16.1x35.9x4.6x
Sun, 23 Mar 2025US$1.9tUS$381.1bUS$41.3b17x45.6x4.9x
Tue, 18 Feb 2025US$1.8tUS$380.9bUS$39.0b18.1x46.9x4.8x
Thu, 16 Jan 2025US$1.8tUS$369.3bUS$31.2b18.5x56.4x4.8x
Sat, 14 Dec 2024US$1.8tUS$373.8bUS$30.6b18.4x59.1x4.8x
Mon, 11 Nov 2024US$1.9tUS$373.7bUS$30.3b21.4x62.8x5.1x
Wed, 09 Oct 2024US$2.0tUS$364.1bUS$25.2b18.2x78.7x5.5x
Fri, 06 Sep 2024US$2.1tUS$364.1bUS$25.5b17.9x80.7x5.6x
Sun, 04 Aug 2024US$1.9tUS$359.3bUS$22.1b15.8x86.8x5.3x
Tue, 02 Jul 2024US$1.9tUS$357.6bUS$13.8b16x140.9x5.4x
Thu, 30 May 2024US$1.9tUS$358.3bUS$14.1b15.8x132x5.2x
Sat, 27 Apr 2024US$1.8tUS$359.5bUS$17.5b22.4x102.8x5x
Mon, 25 Mar 2024US$1.9tUS$355.3bUS$22.6b19.8x82.6x5.3x
Wed, 21 Feb 2024US$1.9tUS$355.0bUS$23.9b28.5x78.6x5.3x
Fri, 19 Jan 2024US$1.7tUS$375.2bUS$33.9b27.7x51.6x4.7x
Sun, 17 Dec 2023US$1.6tUS$375.1bUS$33.9b26.7x48.6x4.4x
Tue, 14 Nov 2023US$1.6tUS$375.5bUS$34.1b26.5x48x4.4x
Thu, 12 Oct 2023US$1.7tUS$381.8bUS$43.8b17.1x39x4.5x
Sat, 09 Sep 2023US$1.8tUS$381.8bUS$43.9b19.1x41.3x4.7x
Mon, 07 Aug 2023US$1.7tUS$379.8bUS$43.1b20.5x39.1x4.4x
Wed, 05 Jul 2023US$1.7tUS$392.8bUS$60.2b18.6x29x4.4x
Fri, 02 Jun 2023US$1.7tUS$393.0bUS$60.5b18.3x27.9x4.3x
Sun, 30 Apr 2023US$1.7tUS$400.2bUS$62.2b17.4x27x4.2x
Tue, 28 Mar 2023US$1.6tUS$401.2bUS$69.5b14.7x22.5x3.9x
Thu, 23 Feb 2023US$1.6tUS$401.7bUS$68.5b17.6x23.6x4x
Sat, 21 Jan 2023US$1.7tUS$403.7bUS$70.6b17.7x23.9x4.2x
Mon, 19 Dec 2022US$1.7tUS$403.7bUS$70.7b16.7x24.6x4.3x
Wed, 16 Nov 2022US$1.7tUS$403.8bUS$70.5b14x24x4.2x
Price to Earnings Ratio

24x


Total Market Cap: US$1.7tTotal Earnings: US$70.5bTotal Revenue: US$403.8bTotal Market Cap vs Earnings and Revenue0%0%0%
U.S. Pharma Industry Price to Earnings3Y Average 52.6x202320242025
Current Industry PE
  • Investors are pessimistic on the American Pharmaceuticals industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 27.9x which is lower than its 3-year average PE of 52.7x.
  • The industry is trading close to its 3-year average PS ratio of 4.7x.
Past Earnings Growth
  • Both revenue and earnings for companies in the Pharmaceuticals industry have remained mostly flat over the last three years.
  • This means that sales and the cost of doing business have remained relatively consistent over this period and subsequently, so have profits.

Industry Trends

Which industries have driven the changes within the U.S. Healthcare industry?

US Market-1.99%
Healthcare0.55%
Pharma2.03%
Pharma2.03%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
LLY Eli LillyUS$924.377.1%
+US$55.1b		11.2%PE45x
TEVA Teva Pharmaceutical IndustriesUS$23.9717.0%
+US$4.0b		40.1%PE38.6x
BMY Bristol-Myers SquibbUS$46.691.3%
+US$1.3b		-13.8%PE15.7x
TERN Terns PharmaceuticalsUS$18.47123.6%
+US$893.5m		153.0%PB5.3x
INVA InnovivaUS$20.8614.6%
+US$412.7m		3.4%PE12.2x

Latest News

MRK
US$86.28
Merck
7D
0.3%
1Y
-16.2%
INVA
US$20.86
Innoviva
7D
14.6%
1Y
3.4%
JNJ
US$186.57
Johnson & Johnson
7D
-1.2%
1Y
20.0%
PRGO
US$14.44
Perrigo
7D
-30.4%
1Y
-45.2%

Perrigo Company plc (NYSE:PRGO) Not Doing Enough For Some Investors As Its Shares Slump 31%

Nov 07
Perrigo Company plc (NYSE:PRGO) Not Doing Enough For Some Investors As Its Shares Slump 31%
LLY
US$924.37
Eli Lilly
7D
7.1%
1Y
11.2%

Eli Lilly (NYSE:LLY) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

Nov 07
Eli Lilly (NYSE:LLY) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of
TEVA
US$23.97
Teva Pharmaceutical Industries
7D
17.0%
1Y
40.1%

TEVA: Stock Will Gain Momentum As Key Drug Pricing Decision Nears

Analysts have increased their price target for Teva Pharmaceutical Industries by approximately $3, citing improved Q3 trends as well as positive expectations for key drug pricing and regulatory developments. Analyst Commentary Recent updates from Street research highlight both optimistic outlooks and ongoing risks for Teva Pharmaceutical Industries as analysts revise their expectations following Q3 performance and future drug pricing developments.
RPRX
US$38.56
Royalty Pharma
7D
2.7%
1Y
47.1%
BLTE
US$113.19
Belite Bio
7D
6.9%
1Y
39.6%
TERN
US$18.47
Terns Pharmaceuticals
7D
123.6%
1Y
153.0%
JAZZ
US$131.16
Jazz Pharmaceuticals
7D
-4.7%
1Y
6.1%
BMY
US$46.69
Bristol-Myers Squibb
7D
1.3%
1Y
-13.8%
SUPN
US$46.02
Supernus Pharmaceuticals
7D
-16.5%
1Y
25.7%

SUPN: Upgrades And Revenue Outlook Will Shape Performance Amid Execution Risk

Analysts have raised their price target for Supernus Pharmaceuticals by over $4 to approximately $59.33 per share. This change is due to higher future revenue growth expectations and an improved outlook for key therapies.
ZTS
US$120.24
Zoetis
7D
-16.6%
1Y
-32.0%
PFE
US$24.43
Pfizer
7D
-0.9%
1Y
-8.6%
INDV
US$31.34
Indivior
7D
6.7%
1Y
205.8%
RGC
US$13.02
Regencell Bioscience Holdings
7D
-21.8%
1Y
7,049.7%